Comprehensive Study of Social Representation of Platelet Transfusion in Patients Followed for Advanced Hematological Malignancies (R-PLQ)
Study Details
Study Description
Brief Summary
Limited data is available for end of life care in hematologic malignancies, moreover with thrombocytopenic patients. Thrombopenia is a frequent complication, specific of bone marrow involvement in those diseases or its treatments. Yet, a few studies was interested in, whereas platelet transfusion is the only treatment indicated. As it represent a scarce, limited resource, the ethical principles are in conflict in this setting and there's a lack of recommendation. The final decision is take by the clinician and his patient, but no study exist in representation of the two parts. We provide a qualitative study to understand what this decision is made of.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| patient patient with advanced, non curative hematological malignancies multi method questionary, at least 1 hour per patient |
Other: multi method questionary (developped by De Rosa, in 1995 and 2014)
questions from an association network according to the subject and the grounded theorise (Glasser and Strauss)
|
| hematologist medical practitioner of platelet transfusion multi method questionary, at least 1 hour per hematologist |
Other: multi method questionary (developped by De Rosa, in 1995 and 2014)
questions from an association network according to the subject and the grounded theorise (Glasser and Strauss)
|
| Nurses nurses working in hematology, practicing platelet transfusion multi method questionary, at least 1 hour per nurse |
Other: multi method questionary (developped by De Rosa, in 1995 and 2014)
questions from an association network according to the subject and the grounded theorise (Glasser and Strauss)
|
Outcome Measures
Primary Outcome Measures
- measure the impact of social representation on platelet transfusion practice [3 months]
inner core and peripheral items of platelet transfusion of each participant will be collected until reaching saturation, it's to say that the repetition of some terms will be measured between each interview thank's to a questionnaire of at least two principals opened questions.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
major patient
-
patient with advanced hematological malignancies
-
patient transfused in platelet regularly (3 time at least in last month)
-
medical practioner, hematologist, prescribing platelet transfusion at least one per week.
-
nurse working in hematology, practicing platelet transfusion at lest one peer week.
Exclusion Criteria:
-
minor patient
-
non communicant patient
-
non transfused platelet patient
-
non voluntary patient or hematologist or nurses
-
non graduated hematologist
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Moracchini | Besançon | France | 25000 |
Sponsors and Collaborators
- Centre Hospitalier Universitaire de Besancon
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
- Jeoffrion C, Dupont P, Tripodi D, Roland-Lévy C. [Social representations of illness: Comparison of "expert" knowledge and "naïve" knowledge]. Encephale. 2016 Jun;42(3):226-33. doi: 10.1016/j.encep.2015.12.007. Epub 2016 Jan 12. French.
- McGrath P, Holewa H. Special considerations for haematology patients in relation to end-of-life care: Australian findings. Eur J Cancer Care (Engl). 2007 Mar;16(2):164-71.
- McGrath P, Leahy M. Catastrophic bleeds during end-of-life care in haematology: controversies from Australian research. Support Care Cancer. 2009 May;17(5):527-37. doi: 10.1007/s00520-008-0506-1. Epub 2008 Sep 23.
- P/2019/413